论文部分内容阅读
目的分析北京地区抗病毒药物对慢性乙肝患者治疗的现状、疗效及对预后的影响。方法采用回顾性前瞻研究的方法。结果干扰素、拉米夫定抗病毒治疗覆盖率约40%。疗程结束时HBVDNA阴转率拉米夫定组最高,但停药随访时180/220例出现反跳。干扰素组HBeAg血清转换率(22.9%)高于其他组,有统计学意义。干扰素及拉米夫定治疗者病情进展较慢且肝硬化、肝癌发生率明显低于非抗病毒组(P<0.001)。E系统转换组的并发症和死亡率明显低于非转换组(P<0.05)。结论北京地区干扰素和拉米夫定抗病毒治疗覆盖率高于其他地区,效果优于其他药物组,但总体疗效仍较低。干扰素等抗病毒治疗能减缓病情进展和减少肝硬化、肝癌的发生率。
Objective To analyze the status, efficacy and prognosis of antiviral drugs in patients with chronic hepatitis B in Beijing. Methods The method of retrospective prospective study. Interferon, lamivudine antiviral treatment coverage of about 40%. HBVDNA overdose lamivudine group the highest at the end of the course of treatment, but 180/220 cases rebound when discontinued. Interferon HBeAg seroconversion rate (22.9%) higher than the other groups, statistically significant. Interferon and lamivudine treatment of patients progressed slowly and cirrhosis, liver cancer incidence was significantly lower than non-antiviral group (P <0.001). Complications and mortality in the E-System conversion group were significantly lower than those in the non-conversion group (P <0.05). Conclusion The coverage of interferon and lamivudine antiviral therapy in Beijing is higher than other regions, and the effect is better than other drug groups, but the overall curative effect is still low. Antiviral therapy such as interferon can slow the progression of the disease and reduce the incidence of cirrhosis and liver cancer.